Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. The Company  delivers  scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome industry-leading neuroscience portfolio includes FDA-approved . . . This content is for …

Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of  extreme bad weather in some states,  problems of important people from Epstein with many people visited him as friends not for anything else. While we enjoyed the surge of Crispr Therapeutics, we decided to remind the …

Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals?  A: Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company that aims at  improving the lives of patients with debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need. The firm  focuses on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong . . . This …

The root-cause of the stock market’s volatility and inflation does not make sense as we are reading and hearing it. At the end of this week, we will post an article about this important subject, which will also explain the reason for the long pause of the Prohost Letter. Let’s have important news... Moderna to Report Q2 2025 Financial Results Moderna, Inc. (

Vertex Pharmaceuticals in the NEWS On Jul. 1, 2025, Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. From . . . This content is for paid subscribers. Please click here …

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer We wanted to know the reason for the acquisition so we looked at the BioNTech press release about the acquisition and found out the following news. On June 12, 2025, BioNTech (BNTX

Vertex Pharmaceuticals Simultaneous Announcements Vertex Pharmaceuticals (VRTX) announced simultaneous presentation and publication of updated data from Phase 1/2 portion of Phase 1/2/3 FORWARD-101 clinical trial in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in oral presentation at the American Diabetes Association (ADA . . . This content is for paid subscribers. Please click here to subscribe …

Cidara Therapeutics Cidara Therapeutics uses its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track …

Exelixis in the NEWS Exelixis (EXEL) announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Biotechnology and biopharmaceutical firms were doing great until the day the COVID-19 pandemic changed the lives of the world's population, killing millions worldwide. This distress impacted humanity's peace, stability and economy, bringing in unparalleled inflation, in addition to wars.    Analysts told investors to buy a stocks and then told them to sell those same stocks a few days later.  This practice made our picked …

Alnylam Pharmaceutical's News Today is Great Before we get to the press release from Alnylam Pharmaceuticals we remind that tomorrow, Tuesday, June 10, 2025,  Akero Therapeutics’ management will present at Goldman Sachs 46th Annual Global Healthcare Conference at 2:40 pm Et. The presentation will be available through the investor relations section of the company’s website at www.akerotx.com. An archived replay will be available for those …

Soleno Therapeutics Soleno Therapeutics (SLNO) announced that’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). From Soleno Therapeutics “The validation . . . This content is for paid subscribers. Please click here to subscribe or …

Vera Therapeutics As expected, Vera Therapeutics (VERA) product Ataticept achieved proteinuria reduction in ORIGIN Phase 3 trials in adults with IgA nephropathy. This is indeed great news! The trial met the primary endpoint at week 36. Ataticept has achieved 46%reduction from baseline and 42%reduction compared to placebo on wek 36. Vera is not sharing cGFR at this time . . . This content is for …

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what we knew before?  A: On May 6th Vera Therapeutics (VERA) provided business  Update and Reported  First Quarter 2025 Financial Results on  track to announce the primary endpoint results from the atacicept pivotal . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Exelixis in the NEWS   Two days ago, Exelixis (EXEL) reported financial results for the first quarter of 2025, providing an update on the firm’s progress toward achieving key corporate objectives, and outlined its commercial, clinical, and pipeline development milestones. From Exelixis Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis said, " Exelixis has delivered outstanding financial performance . . . This content is …

Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. The good day began following the U.S. and China’s announcement of an agreement on Tariffs Many countries have been stressed since being attacked by COVID-19 and then the war in Europe and the Middle East as well as unparallelled inflations.   Yesterday, the Stock market rallied and with it …

PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results for the first quarter ended March 31, 2025. We loved the firm’s strong revenue performance of $190 million,  the positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, and, important is the  NDA review remained on track for July 29, 2025, PDUFA date, the . . . This …

Alnylam Pharmaceuticals Synopsis  Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam Pharmaceuticals, said, “2025 is off to a remarkable start, having ended the first quarter with U.S . . . This …

Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frown lines between the eyebrows, known as glabellar lines. The Product TrenibotE is a botulinum toxin of serotype E with short effects of a long duration for the users. The product is safer than the existing . . . This …